Abstract

Disclosed is a dressing fixation device. An embodiment of the present invention provides a dressing fixation device comprising: a cover part formed by mimicking the shape of a body part including an area to be treated; and a support part disposed along an edge of the cover part and having a thickness greater than the thickness of the cover part, wherein the cover part wraps around one side of the body part, in which the area to be treated is positioned, and the other side opposed to the one side and applies pressure to the area to be treated.

IPC Classes  ?

• A61F 13/00 - Bandages or dressingsAbsorbent pads
• A61F 13/02 - Adhesive bandages or dressings

Abstract

The present invention relates to the formation of an organoid derived from colorectal cancer or sarcoma patient cells. In the present invention, it was confirmed that, when gelatin is used as an alternative material to a basement membrane extract (BME), compared to when a conventional BME is used, the formation of an organoid is more promoted, cancer indicator-related marker expression is more promoted, and structural stability is more improved, and it was also confirmed that metabolic activity is improved on the basis that oxygen consumption of the organoid increases. In addition, a medium for organoid formation of the present invention is more economical than a BME in terms of cost and organoid formation period. Limitations occurring in reproducing biological characteristics of a tumor in a colorectal cancer cell line and sarcoma patient-derived cells may be compensated for through a medium composition utilizing gelatin of the present invention, thereby enabling the provision of a physiologically similar model, and thus the present invention may be utilized in the future as a platform that is useful for preclinical research, diagnosis, and treatment evaluation.

IPC Classes  ?

• C12N 5/09 - Tumour cells

Abstract

The present invention relates to: a support for culturing corneal cells, the support comprising graphene; and a use thereof. The support which is for culturing corneal cells and comprises graphene according to the present invention is non-toxic to corneal cells, is optimized for the cell proliferation rate, adhesion rate, and survival rate of corneal cells, enhances the expression of corneal cell-specific genes, and can maintain an optimized corneal cell state through cytoskeleton remodeling and mitochondrial activation, and thus has the effect of being applicable to cell therapy products, graft materials in the field of regenerative medicine, and platforms for tissue engineering.

IPC Classes  ?

• C12N 5/079 - Neural cells
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor

Abstract

The present invention relates to the use of corneal cell-derived mitochondria for preventing or treating corneal damage or corneal endothelial cell diseases. Mitochondria isolated from corneal endothelial cells differentiated from induced pluripotent stem cells (iPSCs), of the present invention, were confirmed to alleviate inflammatory responses of corneal endothelial cells in an inflammatory environment, restore the integrity and function of corneal endothelial cells, inhibit inflammatory responses, particularly inflammation caused by physical damage, upon delivery into xenogeneic primary corneal endothelial cells, and promote the regeneration of corneal endothelial cells. Therefore, mitochondria having these effects can overcome the oncogenic limitations of conventional stem cell therapeutic agents, and are widely applicable and exhibit excellent cost efficiency due to their ease of production and fewer regulations.

IPC Classes  ?

• A61K 35/30 - NervesBrainEyesCorneal cellsCerebrospinal fluidNeuronal stem cellsNeuronal precursor cellsGlial cellsOligodendrocytesSchwann cellsAstrogliaAstrocytesChoroid plexusSpinal cord tissue
• A61K 35/545 - Embryonic stem cellsPluripotent stem cellsInduced pluripotent stem cellsUncharacterised stem cells
• A61P 27/02 - Ophthalmic agents

Abstract

The present invention relates to a biomarker for prognostic prediction for sepsis, and use thereof. By evaluating the proteomic profile of sepsis patients by using SWATH-MS-based proteomics, PF4, CXCL7, ACTB, FINC, and TIMP1 were respectively identified as novel biomarkers for distinguishing the severity of sepsis and predicting outcomes of sepsis patients in the ICU, and, due to having excellent prognostic predictive performance for sepsis, are expected to be useful for prognostic predictive use and diagnostic use for sepsis, and the like.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The corneal endothelial transplantation device comprises: a balloon in which an expandable/contractible space is formed; and a catheter which provides a fluid for expanding the expandable/contractible space to the balloon. The balloon comprises: a thin-film part; and an expandable/contractible film part which has an edge part fixed to the edge part of the thin-film part such that the expandable/contractible space is formed between the thin-film part and the expandable/contractible film part, and on an outer surface of which a graft for transplantation to a transplantation site is disposed. When the graft is positioned at the transplantation site, the catheter expands the balloon such that the graft is brought into contact with the transplantation site.

IPC Classes  ?

• A61F 2/14 - Eye parts, e.g. lenses or corneal implantsArtificial eyes
• A61F 9/007 - Methods or devices for eye surgery
• A61M 25/10 - Balloon catheters

Abstract

This organ fistula occlusion device comprises: a fistula occlusion film; and a catheter for moving the fistula occlusion film. The catheter comprises: a catheter tube; a guide member movably disposed inside the catheter tube so as to be insertable into and withdrawable from the catheter tube; and a deployment wire which is connected to an end of the guide member so as to be able to unfurl when discharged from the catheter tube, and to which the fistula occlusion film is attached. When the deployment wire is located at a fistula tissue site, the fistula occlusion film is separated from the deployment wire and attached to the fistula tissue site.

IPC Classes  ?

• A61B 17/00 - Surgical instruments, devices or methods

Abstract

The present invention relates to a composition and method capable of effectively predicting the therapeutic responsiveness of a subject to an antibody therapeutic agent for asthma, using blood EDN levels or urine EDN levels. In particular, the present invention can significantly increase the efficiency of predicting therapeutic responsiveness by configuring, as appropriate parameters, blood and urine EDN levels together with the number of blood eosinophils that were conventionally used to predict therapeutic responsiveness to antibody therapeutic agents for asthma. Therefore, the present invention can be usefully utilized for predicting the therapeutic responsiveness of a subject to various antibody therapeutic agents for asthma, such as mepolyizumab, resluzumab, and dupilumab.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present disclosure relates to an antibody binding to CD22, a bispecific antibody including the same, a chimeric antigen receptor, an antibody-drug conjugate, and uses thereof. According to one aspect, effective anticancer effects can be provided even for patients who are refractory to CD19-targeted therapies. Further, when using CD22 CAR NK cells or bispecific CD22/CD19 CAR NK cells, significantly enhanced reduction of cancer cells can be achieved.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present invention relates to an exosome-derived miRNA biomarker isolated from duodenal pancreatic juice for the diagnosis of pancreatic cancer and uses thereof. More specifically, the present invention includes a miRNA biomarker capable of diagnosing pancreatic cancer, a composition for diagnosing pancreatic cancer using same, and a method for providing diagnostic information for pancreatic cancer using same. The miRNA presented in the present invention exhibits excellent diagnostic specificity and sensitivity for pancreatic cancer, and thus can be advantageously used not only for early diagnosis of pancreatic cancer through a non-invasive method, but also for predicting the progression of and therapeutic response for pancreatic cancer.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

An electronic device for de-identifying personal information in clinical information text according to an embodiment comprises: a memory; and a processor for training a machine learning-based de-identification tag generation model on the basis of annotation data indicating a de-identification category for each token of training text and a training dataset including the training text, providing clinical information text for a patient input by medical personnel to the trained de-identification tag generation model, so as to output a de-identification category for each token of the clinical information text, and changing a token corresponding to personal information in the clinical information text into an expression indicating non-personal information on the basis of the output de-identification category.

IPC Classes  ?

• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
• G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
• G06F 21/62 - Protecting access to data via a platform, e.g. using keys or access control rules
• G06F 40/284 - Lexical analysis, e.g. tokenisation or collocates
• G06F 40/169 - Annotation, e.g. comment data or footnotes
• G06F 40/117 - TaggingMarking up Designating a blockSetting of attributes
• G06F 40/151 - Transformation

Abstract

Provided are exosome-derived microRNA biomarkers isolated from duodenal-pancreatic fluid for diagnosing pancreatic cancer, and uses thereof. Particularly, provided are a microRNA biomarker for diagnosing pancreatic cancer, a composition for diagnosing pancreatic cancer using the same, and a method for providing diagnostic information using the same. The microRNAs described herein demonstrate excellent diagnostic specificity and sensitivity for pancreatic cancer, and thus can be usefully employed in a non-invasive manner for early diagnosis of pancreatic cancer, as well as for predicting progression and treatment response of pancreatic cancer.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

In one embodiment, a needle control device for an interventional pain procedure comprises an angle adjustment module and an insertion module, wherein the angle adjustment module includes: a base link; a first link rotatably connected to the base link; a second link rotatably connected to the base link; a third link rotatably connected to the first link; a fourth link rotatably connected to the second link, and rotatably connected to the third link; a first actuator for rotating the first link with respect to the base link; and a second actuator for rotating the second link with respect to the base link, and the insertion module can be fixedly connected to the third link.

IPC Classes  ?

• A61B 17/34 - TrocarsPuncturing needles
• A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
• A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
• A61B 34/00 - Computer-aided surgeryManipulators or robots specially adapted for use in surgery
• A61B 34/35 - Surgical robots for telesurgery
• B25J 9/16 - Programme controls
• A61B 90/50 - Supports for surgical instruments, e.g. articulated arms
• A61B 17/00 - Surgical instruments, devices or methods

Abstract

The present invention relates to a method for preparing pancreatic cancer organoids and a use of pancreatic cancer organoids prepared thereby. A method for preparing pancreatic cancer organoids using collagen and/or POSTN according to an aspect can be used to prepare pancreatic cancer organoids in which a patient's pancreatic cancer tissue and ECM environment thereof are well mimicked, and thus the prepared pancreatic cancer organoids can be used to effectively predict or evaluate the patient's pancreatic cancer prognosis or responsiveness to a specific drug treatment. A method for providing information for diagnosing or predicting the prognosis of pancreatic cancer according to one aspect can be used to effectively diagnose or predict the prognosis of pancreatic cancer by measuring the expression or expression level of POSTN in pancreatic tissue, pancreatic cancer tissue, the ECM thereof, etc.

IPC Classes  ?

• C12N 5/09 - Tumour cells
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/575 -

Abstract

In the present disclosure, in order to accurately classify stages of tumor, lymph node, and metastatic metastasis (TNM) in electronic medical record (EMR) data, a plurality of large language model (LLM) agents and a high-level prompting technique are utilized to analyze medical data and derive a consensus-based results according to majority. Specifically, disclosed are a cancer stage classification automation device and method in which a plurality of different LLM agents are independently applied to each of T, N and M such that error rate is reduced and the reliability of results is improved.

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
• G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
• G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
• G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
• G06N 3/096 - Transfer learning
• G06F 16/3329 - Natural language query formulation
• G06F 16/338 - Presentation of query results
• G06F 16/35 - ClusteringClassification

Abstract

This photodynamic therapy endoscope comprises: an endoscope body in which a working channel is formed; an optical fiber unit that is disposed in the working channel and emits light; and an endoscope cap inserted into an end of the endoscope body. The endoscope cap includes: a membrane coated with a photosensitive agent; and a cap part configured to be selectively connected to the front end of the endoscope body, wherein the membrane is positioned forward of the cap part.

IPC Classes  ?

• A61N 5/06 - Radiation therapy using light

Abstract

The present invention relates to a novel Lactobacillus fermentum HEM20792 strain, a composition comprising the strain or a culture thereof for preventing or treating chronic obstructive pulmonary disease (COPD), and the like. The composition comprising a Lactobacillus fermentum HEM20792 strain (KCTC14066BP) as an active ingredient, according to the present invention, inhibits lung tissue damage and suppresses immune cells, and thus can prevent or treat COPD including emphysema. Therefore, it is expected that the present invention can be used to help cure pulmonary disease by eliminating a fundamental cause of COPD.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 11/00 - Drugs for disorders of the respiratory system
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics

Abstract

The present invention relates to universal immunomodulatory T cells comprising a chimeric antigen receptor and uses thereof and, specifically, to universal immunomodulatory T cells in which immunogenicity of cells is removed so that general T cells obtainable in sufficient numbers from healthy people can be applied to all organ transplant patients and in which Foxp3 and a chimeric antigen receptor are both introduced, and a use thereof.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C07K 14/725 - T-cell receptors
• C07K 14/74 - Major histocompatibility complex [MHC]
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

The present invention relates to a biomarker for predicting therapeutic response in asthma patients and a use thereof, and specifically, to a method for predicting therapeutic response to an anti-interleukin 4 receptor antibody (anti-IL-4R antibody), an anti-interleukin 5 antibody (anti-IL-5 antibody), or an anti-interleukin 5 receptor antibody (anti-IL-5R antibody), which is being used as a therapeutic agent for asthma, by using eicosanoids, and the like.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

A fusion protein may include a Cas protein and a bacterial toxin. Such a fusion protein, a polypeptide thereof, and/or a CRISPR-Cas system including the fusion protein may allow effective base editing. Due to the small size of the polypeptide, the polypeptide can facilitate delivery through vectors. In addition, when indels are accordingly induced, indel efficiency can significantly increase, and for indel induction, the size of nucleotides where indels are formed can also increase, whereby effective utilization can be made for gene knock-out.

IPC Classes  ?

• C12N 9/22 - Ribonucleases
• C12N 9/78 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/90 - Stable introduction of foreign DNA into chromosome

Abstract

The present disclosure relates to an apparatus, a method, and a computer program for detecting cortical-cortical evoked potentials (CCEP) using transcranial magnetic stimulation (TMS). In particular, the apparatus comprises: a communication module for communicating with an external device; a memory storing at least one process for performing CCEP detection using the TMS; and a processor for performing CCEP detection using the TMS according to the process. The processor can be configured to: calculate noise intervals by collecting electroencephalogram (EEG) signals induced by TMS; cluster EEG channels excluding the calculated noise intervals; perform clustering EEG analysis on the basis of representative EEG signals of each cluster; perform individual EEG analysis on the basis of individual EEG signals within each of the clusters; and then detect CCEP signals on the basis of the clustering EEG analysis results and the individual EEG analysis results.

IPC Classes  ?

• A61B 5/383 - Somatosensory stimuli, e.g. electric stimulation
• A61B 5/372 - Analysis of electroencephalograms
• A61N 2/00 - Magnetotherapy
• A61N 2/02 - Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

An IL10RA mutant protein according to one aspect of the present invention solves the issue of commercial IL10RA proteins being impossible to purify, and is a protein with improved purification efficiency. The IL10RA mutant protein is expressed at a similar level similar to the wild-type IL10RA protein, is normally located in the cell membrane, and exhibits the same level of anti-inflammatory signaling activity as the wild-type protein upon IL-10 stimulation, and thus can be effectively used as a protein replacement therapy for the treatment of inflammatory diseases.

IPC Classes  ?

• C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention relates to a use of nicotinamide adenine dinucleotide (NAD) for preventing or treating olfactory disorders. The NAD increases the thickness of olfactory epithelial tissue and promotes the proliferation of olfactory stem cells and the differentiation thereof into olfactory neurons, and thus can effectively restore lost olfactory sense. Therefore, the NAD can be effectively used for preventing, ameliorating or treating olfactory disorders.

IPC Classes  ?

• A61K 31/7084 - Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The present invention relates to novel antibodies or antigen-binding fragments thereof derived from plasma cells in cancer tissues of cancer patients, and uses thereof, and does not bind to normal cells and exhibits the activity of specifically binding to antigens of cancer cells. Therefore, the antibodies or antigen-binding fragments thereof can be effectively used in the diagnosis of cancer and, when bound to drugs such as an anticancer agent, the antibodies or antigen-binding fragments thereof can also be effectively used in the prevention or treatment of cancer and the like. In addition, the antibodies or antigen-binding fragments thereof are human antibodies or antigen-binding fragments thereof derived from plasma cells in the cancer tissues of cancer patients, and thus can be safely used in the diagnosis, prevention, or treatment of human breast cancer without having to undergo humanization in which specific amino acids of the variable region of the antibody are substituted in order to avoid or minimize an immune response in humans.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61P 35/00 - Antineoplastic agents
• C12Q 1/6869 - Methods for sequencing
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to a method for preparing a radiopharmaceutical in which purification is performed by solid phase extraction (SPE) and to a cassette configured to perform the method in an automated synthesis module. By using a solid-phase extraction (SPE) process, the method for synthesizing an 18F-labeled radiopharmaceutical according to the present invention improves reproducibility and shortens synthesis time compared to a conventional HPLC process, thereby enabling production of an 18F-labeled radiopharmaceutical with high purity and high yield. By using a cassette configured to perform the synthesis method according to the present invention in an automated synthesis module, the 18F-labeled radiopharmaceutical can be conveniently synthesized. Accordingly, the method is expected to be advantageously applied to the production of 18F-labeled radiopharmaceuticals.

IPC Classes  ?

• A61K 51/04 - Organic compounds
• C07B 59/00 - Introduction of isotopes of elements into organic compounds
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61J 3/00 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms

Abstract

In the present invention, a deuterium-substituted FP-CIT linear precursor is developed in order to increase the linear stability of a precursor. When the deuterium-substituted FP-CIT linear precursor according to the present invention is dissolved in an organic solvent and stored, linearity is maintained well even at room temperature, and the same effect as a conventional radiopharmaceutical product [1866-[1866-[1866-[18F]FP-CIT enables visualization of dopamine transporter (DAT) distribution to be performed through improved image contrast, and has particularly high accuracy in diagnosing Parkinson's disease and related degenerative brain diseases, and thus can be effectively used.

IPC Classes  ?

• C07D 451/02 - Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamineCyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropaneCyclic acetals thereof
• C07B 59/00 - Introduction of isotopes of elements into organic compounds
• A61K 51/04 - Organic compounds

Abstract

The present invention relates to a composition for inducing differentiation of human induced pluripotent stem cells into insulin-producing cells, and a method for inducing differentiation into insulin-producing cells by using the composition.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A61K 35/39 - PancreasIslets of Langerhans
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

A method and a device for defending an artificial intelligence-based language model from an attack, according to one embodiment, may comprise the steps of: setting any one of a set of suffixes as an initial suffix; updating the set initial suffix by using an artificial intelligence-based training language model trained with a training data set including harmful instructions and safe responses corresponding to the harmful instructions, so as to determine an updated suffix; optimizing the updated suffix with a second gradient algorithm so as to determine a final defense suffix; and applying parameters of the training language model and the final defense suffix to the language model.

IPC Classes  ?

• G06N 3/094 - Adversarial learning
• G06N 3/084 - Backpropagation, e.g. using gradient descent
• G06F 16/338 - Presentation of query results
• G06F 40/20 - Natural language analysis
• G06F 16/3329 - Natural language query formulation

Abstract

The present invention relates to a method for providing information for predicting therapeutic responsiveness or prognosis to transarterial chemoembolization. The gut microbiota of the present invention serves as a biomarker for predicting therapeutic responsiveness or prognosis to transarterial chemoembolization in patients with liver cancer. The gut microbiota of the present invention can be utilized as a potential predictive factor for clinical outcomes of transarterial chemoembolization, can also be used as an adjunct therapeutic target for treatment of liver cancer patients, and enables prediction of survival rates of liver cancer patients who have undergone transarterial chemoembolization. Accordingly, the biomarker of the present invention is expected to be usefully applied as a marker for predicting therapeutic responsiveness or prognosis to transarterial chemoembolization in patients with liver cancer.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• C12Q 1/6869 - Methods for sequencing

Abstract

This cell sheet transplantation apparatus comprises a cell sheet and a catheter for moving the cell sheet. The catheter comprises: a catheter tube; a sheet pad to which the cell sheet is selectively attached; a guide member which is movably disposed inside the catheter tube to enter and exit the catheter tube, and which has an end portion to which the sheet pad is connected; and a control wire disposed inside the guide member to guide the movement of the sheet pad. The catheter further comprises: a catheter hub which is connected to the rear end of the catheter tube and in which the guide member can be moved; a pad adjustment unit which passes through the catheter hub and which is connected to the guide member; and a wire adjuster for guiding the movement of the control wire in the catheter hub.

IPC Classes  ?

• A61B 17/34 - TrocarsPuncturing needles
• A61M 25/01 - Introducing, guiding, advancing, emplacing or holding catheters
• A61F 2/06 - Blood vessels
• A61B 17/00 - Surgical instruments, devices or methods
• A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents

Abstract

Provided is a method of screening for an autophagy modulator. According to the screening method of an aspect, the autophagy modulator can be accurately screened with only a single cell. In addition, screening can be performed without using fluorescent labeling, and thus cytotoxicity and photobleaching that occur when fluorescent labeling analysis methods are used can be prevented, and the limitation of having to monitor only fluorescently labeled markers can be improved.

IPC Classes  ?

• G01N 21/64 - FluorescencePhosphorescence
• G01N 21/41 - RefractivityPhase-affecting properties, e.g. optical path length
• G01N 33/483 - Physical analysis of biological material

Abstract

The present invention relates to a guide RNA targeting a specific mutation in an RS1 gene, a base editor comprising same, and use thereof and, specifically, to: a guide RNA targeting a c.422G>A (p.R141H) mutation found in the RS1 gene of patients with retinoschisis; a base editor comprising same; and use thereof.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 9/78 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
• C12N 9/22 - Ribonucleases
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/86 - Viral vectors
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 27/02 - Ophthalmic agents

Abstract

The present invention relates to a humanized animal model incorporating a retinoschisis gene variant found in human patients and, specifically, to a humanized animal model carrying a c.422G>A (p.R141H) variant identified in the RS1 gene of human patients with retinoschisis, a use thereof, and the like.

IPC Classes  ?

• A01K 67/0278 - Knock-in vertebrates, e.g. humanised vertebrates
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

Biomarkers useful for detecting resistance to platinum-based chemotherapeutic agents (e.g., cisplatin) administered as pre-chemotherapy (NAC) for solid tumors (e.g., muscle-invasive bladder cancer (MIBC)). The biomarkers include glutathione-related genes, the expression levels of which can be used to determine the NAC resistance. The biomarkers are used in a method of determining chemotherapy resistance and in a method of treating a cancer in a subject.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• A61K 33/243 - PlatinumCompounds thereof
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection

Abstract

The present disclosure relates to a transplantable cell therapy product composition for diabetes mellitus that contains an aggregate of insulin-secreting cells derived from stem cells. In the present disclosure, an NF microwell array membrane was fabricated by applying a molding process to an electrospun, permeable, biodegradable polycaprolactone (PCL) NF membrane and thus allows gases and soluble factors to permeate therethrough. The NF microwell of the present disclosure could provide more nutrients to the iPSC aggregates than conventional impermeable PDMS microwells, thus enhancing survival and differentiation capabilities of the cells. Additionally, the NF membrane was attached singly to the subcutaneous tissue and to the surface of organs such as liver and peritoneum without the need for a fixing material or separate sutures and was integrated with surrounding tissues, resulting in higher insulin secretion than PDMS microwells. Therefore, the present disclosure can be effectively utilized as a composition for the prevention or treatment of diabetes.

IPC Classes  ?

• A61K 35/39 - PancreasIslets of Langerhans
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

Provided are a dynamic image data-based object state prediction method and a computer device performing the same. The computing device includes a memory and at least one processor communicating with the memory. The processor obtains early dynamic image data corresponding to an early section after a medicine is injected into a learning object until a preset time point, learns a first prediction model for predicting first image data indicating anatomical information about the learning object corresponding to a time point earlier than a first section by using, as an input, early dynamic image data corresponding to the first section of the early section, and learns a second prediction model for predicting second image data indicating disease-specific information about the learning object corresponding to a reference time point after the early section by using, as an input, early dynamic image data corresponding to a second section of the early section.

IPC Classes  ?

• G06T 7/00 - Image analysis
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

One aspect of the present invention relates to a method for preparing a high-purity corneal endothelial cell population. The method for preparing a high-purity corneal endothelial cell population according to one aspect can not only increase the efficiency of corneal endothelial cell differentiation from stem cells, but can also improve the function, survival rate, and purity of corneal endothelial cells directly differentiated from stem cells.

IPC Classes  ?

• C12N 5/079 - Neural cells

Abstract

The present invention relates to a gene panel for predicting the responsiveness of renal cancer patients to radiotherapy. In the present invention, the responsiveness of patients to stereotactic body radiotherapy can be predicted with high accuracy by only biopsy of a small amount of tissue, thereby maximizing the efficiency of radiotherapy for patients with difficulty in surgery and at the same time, providing the advantage of preserving renal function.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding

Abstract

This ligation structure comprises: an adhesive for ligating a blood vessel; and a clip (10) on which the adhesive is disposed, wherein the clip (10) comprises a biodegradable material. The adhesive comprises a hydrogel and maintains a ligated state of the blood vessel even after a degradation time, which is the time required for the clip (10) to biodegrade in a human body. The clip (10) comprises: a first binding portion on which the adhesive is disposed; a second binding portion on which the adhesive is disposed; and a connecting portion connecting the first binding portion and the second binding portion. When the blood vessel is in a ligated state by the adhesive disposed on the clip (10), the adhesive on the first binding portion and the adhesive on the second binding portion face each other.

IPC Classes  ?

• A61B 17/122 - Clamps or clips, e.g. for the umbilical cord
• A61B 17/00 - Surgical instruments, devices or methods

Abstract

A computing system for generating an SQL query executable in an OMOP CDM, according to an embodiment, may comprise a memory and a processor that: acquires selection criteria content indicating subject selection criteria of a selected clinical trial; acquires one or more split selection criteria; acquires refined selection criteria by providing a generation model with a second prompt indicating refinement of the one or more selection criteria; acquires extracted content by providing the generation model with a third prompt indicating content extraction for each of clinical information types; maps a concept identifier to the extracted content by providing the generation model with a fourth prompt indicating mapping of the concept identifier corresponding to a clinical term to the extracted content; acquires a merged SQL query by merging individual SQL queries for the refined selection criteria, which are acquired by providing the generation model with a fifth prompt indicating generation of an SQL query for selecting a subject of a clinical trial on the basis of the mapped extracted content; and acquires evaluation information about the merged SQL query by providing the generation model with a sixth prompt indicating evaluation of the merged SQL query.

IPC Classes  ?

• G06F 16/242 - Query formulation
• G06F 16/2453 - Query optimisation
• G06F 16/2455 - Query execution
• G06F 16/84 - MappingConversion
• G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
• G16H 70/00 - ICT specially adapted for the handling or processing of medical references
• G06N 3/045 - Combinations of networks
• G06N 3/0475 - Generative networks
• G06N 3/096 - Transfer learning

Abstract

The present invention relates to a composition for the prevention, alleviation, or treatment of fibrotic diseases, containing a Bacillus species strain, a Bacillus species strain spore, each expressing superoxide dismutase, and/or superoxide dismutase. When orally administered, the composition allows the polypeptide with superoxide dismutase activity to remove reactive oxygen species in vivo, thus being helpful for the prevention, improvement, or treatment of fibrotic diseases such as pulmonary fibrosis or hepatic fibrosis.

IPC Classes  ?

• A61K 38/44 - Oxidoreductases (1)
• A61K 35/74 - Bacteria
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The present invention relates to an RNA-based method for predicting the occurrence of immune-related adverse events induced by cancer immunotherapy. As a result of analyzing various factors related to the occurrence of immune-related adverse events induced by cancer immunotherapy in the present invention, it was confirmed that a gene expression-based neutrophil score or immune cell profile is closely associated with the occurrence of immune-related adverse events. Therefore, the neutrophil score or immune cell profile is expected to be effectively used as a biomarker for predicting the occurrence of an immune-related adverse event induced by cancer immunotherapy or efficacy of cancer immunotherapy. In addition, the present invention relates to an RNA-based method for predicting efficacy of cancer immunotherapy. As a result of analyzing various factors related to efficacy to cancer immunotherapy in the present invention, it was confirmed that a gene expression-based tumor necrosis factor (TNF) score or immune cell profile is closely associated with efficacy. Therefore, the TNF score or immune cell profile is expected to be effectively used as a biomarker for predicting efficacy of cancer immunotherapy.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

A composition for detecting ICAM1 protein comprising the anti-ICAM1 antibody of the present invention can selectively detect the protein by recognizing the N-glycan of ICAM1 that is cancer cell-specifically modified. The composition for detecting ICAM1 protein comprising an anti-ICAM1 antibody according to the present invention can selectively detect the corresponding protein by recognizing the N-glycan of ICAM1 that is cancer cell-specifically modified. In particular, the anti-ICAM1 antibody contained in the composition specifically recognizes and binds to a structure in which sialic acid residues at the N-glycan terminal linked to the N130 asparagine residue of ICAM1 are reduced or deficient, that is, a hyposialylated glycosylation pattern. By targeting a glycosylation pattern appearing only in cancer cells, the antibody provides high therapeutic stability due to low non-specific binding to normal cells. Accordingly, the present invention offers an anti-ICAM1 antibody that precisely targets a cancer-specific glycan pattern and a novel immune-oncology therapeutic strategy based thereon, thereby overcoming limitations of existing anticancer agents and providing enhanced cancer treatment effects.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present invention relates to a novel compound and anticancer uses thereof and, more specifically, provides: a novel compound exhibiting inhibitory activity against HSP90, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition for preventing or treating cancer diseases comprising same; and a health functional food composition for preventing or improving cancer diseases comprising the compound.

IPC Classes  ?

• C07D 307/68 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/42 - Oxazoles
• A61P 35/00 - Antineoplastic agents
• C07D 261/18 - Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives

Abstract

A system for text generation according to one embodiment may comprise one or more processors that select one summary candidate from among summary candidates obtained by providing, to a machine-learning-based summary generation model, summary-generation content instructing the machine-learning-based summary generation model to summarize a plan, obtain a weight by providing, to a machine-learning-based classification model, a prompt including query content containing a query inputted by a user and input content (220) including the plan and the selected summary candidate, obtain a query vector by providing the prompt to a machine-learning-based encoder model, generate one or more pieces of reference data by using pre-written plans and rule documents defining rules retrieved from a database on the basis of the query vector, calculate, for each token recognizable by a large language model (LLM), a first generation probability based on the prompt, a second generation probability based on the one or more pieces of reference data and the prompt, and a generation probability according to the weight by providing the one or more pieces of reference data and the prompt to the machine-learning-based generation model, and generate output text by sequentially selecting generation tokens from among a plurality of tokens on the basis of generation probabilities individually calculated for the plurality of tokens.

IPC Classes  ?

• G06F 16/34 - BrowsingVisualisation therefor
• G06F 16/3329 - Natural language query formulation
• G06F 16/338 - Presentation of query results
• G06F 16/334 - Query execution
• G06F 16/31 - IndexingData structures thereforStorage structures
• G06F 16/35 - ClusteringClassification
• G06F 40/284 - Lexical analysis, e.g. tokenisation or collocates
• G06F 18/2135 - Feature extraction, e.g. by transforming the feature spaceSummarisationMappings, e.g. subspace methods based on approximation criteria, e.g. principal component analysis
• G06F 18/241 - Classification techniques relating to the classification model, e.g. parametric or non-parametric approaches

Abstract

The present invention relates to a method for diagnosing whether anticancer therapy will exhibit responsiveness in a particular patient. The anticancer therapy may include chemotherapy or cancer immunotherapy. Specifically, whether anticancer therapy will exhibit responsiveness in a particular patient can be confirmed through a TCTP level in the plasma of the corresponding patient. In such an aspect, the present invention also relates to use of plasma TCTP as a biomarker indicative of responsiveness to anticancer therapy.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/535 - Production of labelled immunochemicals with enzyme label
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61K 33/243 - PlatinumCompounds thereof
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to an antibody that specifically binds to β2-microglobulin (β2m) and to uses thereof, in which the antibody specifically binds to free β2m protein that has dissociated from MHCI. The antibody or an antigen-binding fragment thereof binds to both the monomer and amyloid forms of β2m, and can detect the monomer and amyloid forms of free β2m in body fluids of dementia and kidney-disease animal models, and thus is useful as an antibody for diagnosing these diseases. In addition, the antibody or an antigen-binding fragment thereof protects damage to cognitive functions induced by β2m in normal mice, and exhibits: reduced amyloid beta and inflammation in the brain after intraperitoneal administration to a dementia mouse model; reduced renal fibrosis and biomarkers in a renal fibrotic disease animal model; and reduced liver fibrosis in a liver fibrotic disease animal model, and thus is useful for preventing and/or treating these diseases.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 14/725 - T-cell receptors
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Genetic markers and a method for the diagnosis or prognosis of degenerative temporomandibular joint osteoarthritis. The method involved detection of a mutation of one or both of SMARCA2 and NOTCH1 or a mutant protein encoded thereby. The detection can be determined from a biological sample, such as saliva, which can be obtained by a non-invasive method. The method involves a random forest-based deep & wide model that is constructed by a machine learning (deep learning) method taken together with the genetic marker mutation information and has excellent diagnostic and predictive abilities with an accuracy of 97%.

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G06N 20/00 - Machine learning
• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
• G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

Abstract

A blood flow volume quantification system based on a blood flow modeling includes: an image receiver configured to receive 4D flow magnetic resonance imaging (MRI) images and MRI images of a plurality of non-diseased individuals; a representative model generation unit configured to perform vessel segmentation based on the received MRI images and to designate a representative model from among the MRI images in which vessel segmentation has been performed, based on a predetermined criterion; an integrated model generation unit configured to register MRI images of other non-diseased individuals to the representative model to generate an integrated model; and a standard blood flow model generation unit configured to register the 4D flow MRI images to the integrated model to generate a standard blood flow model.

IPC Classes  ?

• A61B 5/026 - Measuring blood flow
• G06T 7/00 - Image analysis
• G06T 7/10 - SegmentationEdge detection
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders

Abstract

Provided are a device, method and program for searching and training a preferred retinal locus of a patient with visual field damage. The method comprises the steps of: providing first stimulation to a patient by means of a stimulation providing device linked to the device; receiving, from the patient, a response with respect to the first stimulation by means of the stimulation providing device; if the response is correct, analyzing the movement of the patient's head corresponding to the first stimulation; specifying a preferred retinal locus on the basis of the analysis result; performing training associated with the patient's central fixation; and performing training associated with reinforcement of the patient's preferred retinal locus.

IPC Classes  ?

• A61B 3/024 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for determining the visual field, e.g. perimeter types
• A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb

Abstract

Lacticaseibacillus rhamnosus Lacticaseibacillus rhamnosus HLL-002 strain; a probiotic composition comprising same; a health functional food composition comprising the composition; and a pharmaceutical composition for preventing or treating allergic diseases, comprising the strain.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61P 37/08 - Antiallergic agents
• C12R 1/01 - Bacteria or actinomycetales

Abstract

The present disclosure relates to an infant and toddler motion analysis device and to a method therefor. The device comprises: a memory storing a process for analyzing motions of an infant or toddler; and a processor for executing the process, wherein the processor may determine whether a motion occurs in each of a plurality of body parts of the infant or toddler on the basis of acceleration data measured from sensors respectively attached to the plurality of body parts, and determine whether the motions of the infant or toddler are normal on the basis of the acceleration data measured for the plurality of body parts in which the motions are determined to have occurred.

IPC Classes  ?

• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

CandidaCandida sp. fungus; an antibacterial composition comprising same; and a pharmaceutical composition for preventing or treating diseases caused by pathogenic fungi. The ASO according to the present invention can be used as a gene therapeutic agent having a fungus-specific antibacterial effect by specifically inhibiting FKS1, FKS2, CHS3 and/or GWT1 genes, and can be a useful gene therapeutic agent that can be used in combination with or replace conventional antifungal agents for antifungal agent-resistant fungi or multidrug-resistant fungi.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A01N 63/60 - Isolated nucleic acids
• A01P 3/00 - Fungicides
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61P 31/10 - Antimycotics

Abstract

The present invention relates to: a method for differentiating stem cell-derived hepatocytes by using fasudil and gelatin; and the like. The method for differentiating stem cell-derived hepatocytes, according to the present invention, induces, by means of fasudil, the differentiation of stem cells into endoderm in an early stage of differentiation of stem cells into hepatocytes, inhibits lipid droplet formation through high-viscosity gelatin coating of a culture container, activates mitochondrial functions, up-regulates the expression of endoderm genes, and down-regulates the expression of ectoderm and mesoderm genes, thereby improving the efficiency of differentiation of stem cells into hepatoblasts. In addition, low-viscosity gelatin is added to the medium in a differentiation and maturation (late) stage so as to suppress the accumulation of lipid droplets, mitochondria are activated to improve the efficiency of differentiation of hepatoblasts into hepatocytes, and the function of differentiated hepatocytes is enhanced to improve the efficiency of differentiation of stem cells into hepatocytes. Therefore, hepatocytes obtained using the method are expected to be effectively used as a cell therapeutic agent, a transplant, and the like for treating liver diseases.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

The present invention provides a painless lymph-targeted drug delivery patch comprising: a patch part having one side attached to a skin surface and having multiple through-holes through which a drug passes; multiple microneedle parts arranged along a pattern configured on one side of the patch part to inject the drug while being inserted into the skin; a drug chamber provided on the other side of the patch part to supply the drug to the microneedle parts through the through-holes; and an adsorption part provided on the other side of the patch part to selectively form negative pressure on the other side surface of the patch part or the skin surface.

IPC Classes  ?

• A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
• A61M 5/42 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for desensitising skin, for protruding skin to facilitate piercing, or for locating point where body is to be pierced
• A61M 5/142 - Pressure infusion, e.g. using pumps
• A61M 5/158 - Needles

Abstract

The present invention relates to a method for paper-based innovative nucleic acid extraction without centrifugation (PINE-CX) and a method for detecting nucleic acids in a sample using same. In the method according to an aspect, nucleic acids can be extracted and amplified from a sample with only a simple operation in a short time without centrifugation, and thus nucleic acid extraction and amplification efficiency is remarkably excellent. As a result, nucleic acids in a sample can be detected with high efficiency, and thus the method can be usefully used even in point-of-care testing (mPOCT) with limited resources.

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/6844 - Nucleic acid amplification reactions
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

Abstract

Provided is a method for tracking patient symptoms through a dialog system using a language model. The method comprises the steps of: extracting, through a router chain of a dialog system, at least one side effect list on the basis of a query message and a response message input by a patient with respect to the query message; routing to an inspection chain of the dialog system corresponding to the side effect list; and providing, through the inspection chain, a side effect grade on the basis of an additional response message input by the patient with respect to an additional query message based on the side effect list.

IPC Classes  ?

• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
• G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
• G06N 3/0475 - Generative networks
• G06N 3/096 - Transfer learning
• G06N 3/0895 - Weakly supervised learning, e.g. semi-supervised or self-supervised learning
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

The present invention relates to an anti-apolipoprotein E4 (ApoE4) antibody and use thereof and, more specifically, to: an anti-ApoE4 antibody or an antigen-binding fragment thereof; a fusion in which the anti-ApoE4 antibody or an antigen-binding fragment thereof and one or more blood-brain barrier (BBB) receptor-binding peptides are bound; a method for preparing the fusion; and a composition for preventing or treating neurodegenerative diseases or metabolic diseases, comprising the anti-ApoE4 antibody or an antigen-binding fragment thereof, or the fusion.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/16 - Anti-Parkinson drugs
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to a XIAP protein variant or a fusion protein comprising same, and use thereof. The XIAP protein variant according to one embodiment has an effect functionally equivalent to that of a wild-type XIAP protein, promotes ubiquitination of receptor-interacting serine/threonine-protein kinase 2 (RIP2) so as to activate NOD signaling, and has increased residual time and levels in cells relative to the wild-type XIAP protein, and thus can be effectively used in the treatment of inflammatory diseases, particularly diseases caused by NOD signaling defects.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

Disclosed is a method for analyzing a heart sound by an electronic device for measuring a preload of a general anesthesia surgery patient including splitting a heart sound and a breathing sound from heart-lung sound data of a patient obtained externally, specifying a breathing section from the split breathing sound, obtaining a heart sound envelope for obtaining a peak signal by converting a heart sound signal, obtaining a heart sound index from the heart sound envelope, and calculating an acoustic variability index (AVI) by analyzing the heart sound index.

IPC Classes  ?

• A61B 7/00 - Instruments for auscultation
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/026 - Measuring blood flow

Abstract

The present invention relates to an apparatus and a method for refining bio-signal artifacts and, more specifically, comprises: a database in which bio-signals are stored; an extraction unit for extracting only clean signals from among the bio-signals; an augmentation unit for generating augmented artifacts by augmenting the clean signals; a storage unit for storing the clean signals and the augmented artifacts; a training unit for training a refining model by using a dataset generated on the basis of the augmented artifacts; and a refining unit for refining artifacts of the bio-signals by using the refining model, wherein previously unusable data is refined and converted into useful information, and thus the range of use of data can be widened, and both the quality and amount of clinical data can be improved by reducing data loss.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G06N 3/08 - Learning methods

Abstract

The present invention relates to a spiral epidural catheter. The spiral epidural catheter comprises: a catheter body having a passage formed therein and an inlet/outlet hole formed at a tip of a distal end part thereof, wherein a procedure tool is insertable into the passage, the distal end part faces a lesion target, the inlet/outlet hole communicates with the passage and allows the procedure tool to enter and exit therethrough, and the distal end part is tapered with a cross-sectional area gradually reduced toward the inlet/outlet hole; and a spiral part protruding or recessed in a spiral shape on an outer circumferential surface of the distal end part of the catheter body.

IPC Classes  ?

• A61B 17/34 - TrocarsPuncturing needles
• A61M 25/00 - CathetersHollow probes

Abstract

The present invention relates to a DNA methylation marker for diagnosing colon cancer and uses thereof and, more specifically, to: a combination of DNA methylation markers capable of determining the presence or absence of colon cancer; and uses thereof. The DNA methylation marker for diagnosing colon cancer, according to the present invention, can diagnose colon cancer with high accuracy by using only DNA methylation information of blood samples, without using colon cancer tissue samples, and thus can be effectively used for early diagnosis of colon cancer.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism

Abstract

The present invention relates to a method for providing information for the diagnosis and/or prognosis of aortic valve stenosis, and was arrived at by discovering that an increase in anti-citrullinated peptide antibody levels is associated with the onset and prognosis of aortic valve stenosis. The present inventors discovered that the accurate early diagnosis of aortic valve stenosis is possible through measuring anti-citrullinated peptide antibody levels, and the degree of aortic valve deformity, severity, and probability of complications such as hypertension, rheumatoid arthritis, and interstitial lung disease can be predicted, and thus the anti-citrullinated peptide antibody is expected to be used as a biomarker for more effective diagnosis, prognosis, and treatment of aortic valve stenosis.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Disclosed is an articulated device including a base member, a shuttle member disposed in the base member to be movable to any one of a first position or a second position disposed to be spaced apart from the first position on the base member, and a unit joint provided between the base member and the shuttle member to be movable in the base member together with the shuttle member, and including an elastic member that generates an elastic force to the base member and the shuttle member.

IPC Classes  ?

• B25J 9/06 - Programme-controlled manipulators characterised by multi-articulated arms
• A61B 34/30 - Surgical robots
• B25J 9/10 - Programme-controlled manipulators characterised by positioning means for manipulator elements

Abstract

The present invention relates to a pain evaluation model generation method. One embodiment of the present invention provides a pain evaluation model generation method comprising the steps of: acquiring a photoplethysmogram signal of a subject; selecting at least one input index from the acquired photoplethysmogram signal; and generating a pain evaluation model capable of evaluating the pain of the subject by performing machine learning using the selected input index as input data, wherein the acquired photoplethysmogram includes a first photoplethysmogram acquired at a first time point at which the subject is anesthetized and a second photoplethysmogram acquired at a second time point at which the subject recovers from the anesthesia after the first time point.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/024 - Measuring pulse rate or heart rate
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G06N 20/20 - Ensemble learning

Abstract

The present invention relates to a pyrrolopyrimidinone carboxamide compound represented by Chemical Formula 1, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for treating cancer, comprising the same as an active ingredient. Specifically, the compound increases plasma stability so that, until the compound reaches cancer cells, the structure thereof is maintained, and thus the compound exhibits anticancer effects greater than those of existing compounds.

IPC Classes  ?

• C07H 19/14 - Pyrrolo-pyrimidine radicals
• A61K 31/7064 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
• A61P 35/00 - Antineoplastic agents

Abstract

A fusion protein, according to one aspect, enables effective base editing within organelles, and provides an effect of enabling genetic base editing of both cell nucleus and organelles by using a single fusion protein.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 9/78 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

This microneedle patch comprises: a sheet; a biodegradable needle, which is detachably connected to the sheet, extends in one direction from the sheet, and has a drug accommodation part formed therein; and a photosensitizer disposed to encompass the outer surface of the biodegradable needle. The photosensitizer is disposed to be coated on the outer surface of the biodegradable needle, and the biodegradable needle is elongated beyond the thickness of the sheet.

IPC Classes  ?

• A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
• A61N 5/06 - Radiation therapy using light

Abstract

The present invention relates to a bacterial toxin variant and use thereof. According to an aspect, a variant, a fusion protein, a polypeptide thereof, and a base editing system including same facilitate binding with Cas proteins because the polypeptide size is small, and compared to an existing base editing system using Ssda proteins, base editing efficacy is significantly improved, enabling more effective base editing, and base editing is also possible in cell organelles.

IPC Classes  ?

• C12N 9/22 - Ribonucleases
• C12N 9/78 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

Abstract

Disclosed is an operating method of a medical image processing device using augmented reality (AR) including obtaining, from a first external device, a first image including blood vessel information and bone tissue information according to tomography, obtaining, from a second external device, a second image including a facial structure and a facial curve according to 3D imaging, extracting a facial feature point from facial unique information including the blood vessel information, the bone tissue information, the facial structure, and the facial curve, registering the first image to the second image based on the facial feature point, generating a composite image by performing 3D-modeling on the first image registered with the second image, projecting the composite image onto a face of a patient, and displaying, on a projected image, a first layer corresponding to the blood vessel information and a second layer including the bone tissue information.

IPC Classes  ?

• G06T 7/33 - Determination of transform parameters for the alignment of images, i.e. image registration using feature-based methods
• A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
• G06T 7/73 - Determining position or orientation of objects or cameras using feature-based methods
• G06T 19/00 - Manipulating 3D models or images for computer graphics
• G06V 40/16 - Human faces, e.g. facial parts, sketches or expressions

Abstract

The present disclosure relates to an apparatus and method for early evaluation of lymphedema occurrence by determining the regularity of lymphatic contractions, the apparatus comprising a memory for storing at least one instruction for early evaluation of lymphedema occurrence, and a processor for performing operations according to the instruction, wherein the processor: monitors, by using indocyanine green lymphography, the occurrence of lymphedema in an animal model in which lymph nodes have been resected to disconnect lymphatic circulation in an upper limb from the proximal region; measures lymphatic contraction signals at a distal site to detect the onset of and changes in lymphatic circulation disorder; compares the measured lymphatic contraction signals with the lymphatic contraction signals from a normal site; monitors changes in the lymphatic contraction signals at the distal site; and determines the presence of lymphedema on the basis of the monitoring results.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges

Abstract

Disclosed is a microneedle drug delivery stent capable of locally delivering a drug into a luminal organ. The microneedle drug delivery stent comprises: a coating stent; and a microneedle formed in the coating stent to carry a drug, wherein the coating stent may have a coating groove in which the microneedle is formed.

IPC Classes  ?

• A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
• A61F 2/848 - Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents having means for fixation to the vessel wall, e.g. barbs
• A61F 2/90 - Stents in a form characterised by wire-like elementsStents in a form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
• A61F 2/04 - Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts

Abstract

The present disclosure relates to an apparatus and method for detecting a lymphatic contraction signal in real time, wherein the apparatus includes: a contrast medium injection module for injecting a fluorescent material including a lymphatic contrast medium into a subcutaneous interstitial fluid through a drug delivery system; a conversion module that obtains an optical signal by tracking the fluorescent material and converts the obtained optical signal into an electrical signal; a signal processing module that sets the electrical signal as a target signal and removes noise from the set target signal; an analysis module for analyzing the target signal from which the noise has been removed; and an output module that visualizes a result of analyzing the target signal and transmits same to an output device.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

A cage-type electric pulse catheter comprises: a handle; a catheter tube connected to the handle; a catheter rod movably disposed inside the catheter tube to allow the end thereof to be able to enter and exit from the catheter tube; a rod tip coupled to the end of the catheter rod; a leaflet member which is disposed on an outer surface side of the catheter rod and can be selectively unfolded in the outer diameter direction of the catheter rod when the catheter rod moves in the longitudinal direction; and a leaflet electrode disposed on the leaflet member.

IPC Classes  ?

• A61B 18/14 - Probes or electrodes therefor
• A61B 17/00 - Surgical instruments, devices or methods
• A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body

Abstract

This stent comprises: a main body part including a drainage passage and an installation passage; and a removal string inserted into and fastened to the installation passage. The installation passage extends inside the main body part in the front-rear direction and passes through the main body part, and the removal string is inserted into the installation passage so as to extend frontward from the front end of the installation passage and extend rearward from the rear end of the installation passage. A protrusion part is further included, which protrudes toward the drainage passage from an inner surface of the main body part that forms the drainage passage and extends along the inner surface in the front-rear direction, wherein the installation passage is formed to span the main body part and the protrusion part.

IPC Classes  ?

• A61F 2/95 - Instruments specially adapted for placement or removal of stents or stent-grafts
• A61F 2/82 - Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents

Abstract

This rhinitis catheter comprises: a main body for providing a refrigerant container for accommodating a refrigerant, and a mounting space in which the refrigerant container can be accommodated; a valve assembly for selectively discharging the refrigerant from the refrigerant container; a switch unit capable of controlling the operation of the valve assembly; and a sheath unit for guiding, to the nasal cavity, the refrigerant discharged from the refrigerant container. The valve assembly includes: a valve block which is disposed in the mounting space so as to enable communication with the refrigerant container, and which provides a block channel for guiding the discharge of the refrigerant; a fixing ring coupled to the block channel; a supporter which is coupled to the fixing ring and which has a supporter flow path formed therein; and an opening/closing member which is disposed in the supporter flow path so as to be liftable/lowerable, and which can selectively block the block channel by means of the operation of the switch unit.

IPC Classes  ?

• A61M 11/00 - Sprayers or atomisers specially adapted for therapeutic purposes
• A61M 15/08 - Inhaling devices inserted into the nose
• A61M 16/20 - Valves specially adapted to medical respiratory devices
• A61M 39/22 - Valves or arrangement of valves

Abstract

The present invention relates to a stem cell spheroid therapeutic agent for preventing or treating a temporomandibular joint disease and a method for producing same. Specifically, the stem cell spheroid therapeutic agent comprises, as an active ingredient, stem cell spheroids overexpressing at least one gene selected from the group consisting of IDO and FGF2, and when used, prevents cartilage loss in temporomandibular joints and promotes bone regeneration, and has an anti-inflammatory effect, and thus can be effectively used for the fundamental prevention and treatment of temporomandibular arthritis.

IPC Classes  ?

• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Abstract

The present disclosure relates to a visual perception learning-based apparatus and method for providing stereovision training, the apparatus including: a display module; a memory storing at least one stereovision training-based process for improving strabismus; and a processor that generates first stimulus plate for orthophoria among the both eyes of a trainee and a second stimulus plate for strabismus among the both eyes, and provides the stereovision training by adjusting of a difficulty level of a first stimulus among a plurality of stimuli included in each of the first stimulus plate and the second stimulus plate, wherein the difficulty level can be adjusted through at least one of a three-dimensional effect setting of the stimulus, a shape setting of the stimulus, an interval setting of the stimulus, an edge setting of the stimulus, and a background color setting of the stimulus.

IPC Classes  ?

• A61H 5/00 - Exercisers for the eyes
• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
• G02B 27/01 - Head-up displays
• A61F 9/02 - Goggles

Abstract

The present invention relates to a pharmaceutical composition for preventing cancer comprising thymic cells or thymic epithelial cells as an active ingredient, and can prevent cancer by using thymic cells or thymic epithelial cells from childhood. The present invention can be helpfully utilized as a composition for preventing cancer in that thymic cells or thymic epithelial cells, which naturally degenerate after a certain period of time, can be used, and the extracted thymic cells or thymic epithelial cells can be easily treated through autograft.

IPC Classes  ?

• A61K 35/26 - LymphLymph nodesThymusSpleenSplenocytesThymocytes
• A61P 35/00 - Antineoplastic agents

Abstract

An RF catheter for treating hypertrophic cardiomyopathy includes: a body part constituting a catheter body made of a flexible and soft material; and an intraseptal insertion part provided at a distal part of the body part and having one or more electrodes, a tapered tip gradually becoming thinner toward an end thereof, and a guidewire lumen therein, into which a guidewire is inserted, so that during hypertrophic cardiomyopathy treatment, the intraseptal insertion part is inserted into the interventricular septum along the guidewire. A method of treating hypertrophic cardiomyopathy by using an RF ablation catheter includes: i) positioning the guidewire to a hypertrophied septum through a coronary sinus and a septal vein; ii) transferring the RF ablation catheter to the hypertrophied septum; and iii) performing RF ablation by applying RF energy to the electrodes provided at an end part of the RF ablation catheter by using an RF generator.

IPC Classes  ?

• A61B 18/14 - Probes or electrodes therefor
• A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body

Abstract

Disclosed are a CT image processing method and a CT image processing apparatus for detecting and segmenting a perforator in a CT image. The CT image processing method may comprise the steps of: detecting, from a CT image, a region of interest (ROI) expected to have a perforator, by using an ROI detection model; generating a plurality of three-dimensional patches including at least a portion of the detected ROI; and inputting the plurality of three-dimensional patches to a perforator detection model and generating a result image obtained by extracting the perforator from the CT image on the basis of a segmentation result from the perforator detection model.

IPC Classes  ?

• A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
• A61B 6/50 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body partsApparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific clinical applications
• A61B 6/03 - Computed tomography [CT]
• G06T 7/11 - Region-based segmentation

Abstract

The present disclosure relates to a haptic interface device for a remote vascular intervention procedure, comprising: a tube; a plurality of segments concentrically coupled with the tube; an opening formed on the periphery of the plurality of segments such that a user can move a main body by using his/her finger; an encoder for outputting an electrical signal by sensing at least one of a change in position, a direction, and an angle of the plurality of segments; a first motor unit configured in conjunction with the encoder and outputting feedback corresponding to the movement of the plurality of segments; a second motor unit for outputting feedback corresponding to the movement of the plurality of segments; and a processor for outputting a control signal for controlling the first motor, the second motor, and a slave robot, thereby operating the slave robot that moves a surgical tool in response to displacement data sensed by the encoder.

IPC Classes  ?

• A61B 34/00 - Computer-aided surgeryManipulators or robots specially adapted for use in surgery
• A61B 34/35 - Surgical robots for telesurgery
• A61B 34/37 - Leader-follower robots

Abstract

An artificial structure for preventing or treating lymphedema and a construction method therefor. The artificial structure includes a first sheet and a second sheet arranged on the first sheet and including at least two channels. Each channel includes an inlet, an outlet, a one-way channel structure configured to maintain a one-way flow of lymph from the inlet toward the outlet, and a pattern on a surface facing the first sheet. The artificial structure is configured to maintain a normal flow of lymph despite the effects of lymphadenectomy and radiation exposure. The artificial structure has the effect of not only preventing the onset of lymphedema but also effectively being useful for treating diseases caused by interruption of lymph flow.

IPC Classes  ?

• A61M 27/00 - Drainage appliances for wounds, or the like

Abstract

A vascular therapy recommendation apparatus according to an embodiment may comprise: a processor that selects a target vascular image including a target blood vessel from among medical images obtained by photographing the target blood vessel in a plurality of directions, on the basis of a result of applying a first machine learning model to the medical images, selects a representative frame image including the target blood vessel from among a plurality of frame images included in the selected target vascular image, on the basis of a result of applying a second machine learning model to the plurality of frame images, generates input data including time series information by stacking the selected representative frame image, a previous frame of the representative frame image, and a subsequent frame of the representative frame image in order of photographing time, and recommends treatment guide information for the target blood vessel among pieces of candidate treatment guide information by applying a third machine learning model to the stacked input data; and a display for outputting the treatment guide information.

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
• G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G06N 20/00 - Machine learning
• G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
• A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
• A61B 6/50 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body partsApparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific clinical applications
• G06V 20/40 - ScenesScene-specific elements in video content

Abstract

The present invention relates to a stem cell therapeutic agent for preventing or treating temporomandibular joint diseases, and a production method therefor. Specifically, stem cells overexpressing at least one gene selected from the group consisting of IDO, TSG -6, and FGF2 are included as an active ingredient. When used, the agent can prevent cartilage loss in the temporomandibular joint and promote bone regeneration, and thus can be advantageously used for the fundamental prevention and treatment of temporomandibular arthritis.

IPC Classes  ?

• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• C12N 5/0789 - Stem cellsMultipotent progenitor cells
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

Disclosed are an apparatus and a method for predicting a bed occupancy rate in a hospital. The method for predicting a bed occupancy rate, performed by the apparatus for predicting a bed occupancy rate, according to an embodiment, may comprise the steps of: periodically collecting bed information data including information indicating whether a patient occupies each bed and hospital room identification information indicating a corresponding bed; generating, from the collected bed information data, ward data based on patient occupancy information dependent on the time in a ward including each bed; generating, from the collected bed information data, hospital room data based on at least one of patient occupancy information dependent on the time in a hospital room including each bed or time-independent hospital room identification information; training a machine learning-based occupancy rate prediction model by using training data generated on the basis of dividing at least one of the ward data and time-dependent information among the hospital room data into units of predetermined time periods; and applying the trained machine learning-based occupancy rate prediction model to input bed information data, so as to output occupancy rate information for at least one of a ward or a hospital room.

IPC Classes  ?

• G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
• G06N 20/00 - Machine learning

Abstract

The present invention relates to a composition for enhancing the anticancer effect of sorafenib, comprising a SASH1 overexpression vector as an active ingredient. The composition comprises a polynucleotide sequence for inducing the overexpression of SASH1 (SAM and SH3 domain-containing protein 1) comprising a sequence commonly expressed by isoforms of a SASH1 gene. Since the vector of the present invention has an excellent anticancer effect by itself while increasing the anticancer effect of sorafenib, the composition comprising the SASH1 overexpression vector and/or sorafenib as an active ingredient can be usefully used as a substance for preventing or treating cancer.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to: a biomarker composition comprising AMPD3 for predicting sensitivity to a therapeutic agent for neurofibromatosis (NF1); a pharmaceutical composition comprising an AMPD3 inhibitor for preventing or treating NF1; and use thereof. The composition according to one aspect is highly useful as a diagnostic marker for therapeutic agent sensitivity in patients with NF1, and can be used as a new therapeutic target for NF1.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• A61K 31/4245 - Oxadiazoles

Abstract

The present invention relates to an injection control device and an operating method thereof. The injection control device according to one embodiment may comprise: a body to which a linear body including an injection needle connected to a tube integrating outlets of a plurality of cylinders is rotatably connected; a controller for receiving, from a user, a control manipulation instructing at least one of an operation for relative movement between a subject and the body, an operation for rotation of the linear body with respect to the body, or an operation for forward movement of the injection needle; and a processor for controlling the operation of at least one of the body, the linear body, or the injection needle on the basis of the control manipulation input through the controller.

IPC Classes  ?

• A61M 5/42 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for desensitising skin, for protruding skin to facilitate piercing, or for locating point where body is to be pierced
• A61M 5/14 - Infusion devices, e.g. infusing by gravityBlood infusionAccessories therefor
• A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
• A61M 5/48 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for varying, regulating, indicating or limiting injection pressure
• A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
• A61M 19/00 - Devices for local anaesthesiaDevices for hypothermia
• A61M 5/142 - Pressure infusion, e.g. using pumps
• A61M 5/158 - Needles

Abstract

The present invention demonstrates the functional enhancement of melatonin-primed stem cells through ten indicators including self-renewal ability, engraftment rate, anti-inflammatory ability, and immunosuppressive ability in a cell culture model. It has been identified that in the primed stem cells according to the present invention, the activity of glutathione (GSH) is increased, through signaling involving cyclic adenosine monophosphate (cAMP) response element-binding protein-1 (CREB1) and nuclear factor (erythroid-derived-2) like-2 (NRF2) as a molecular mechanism and, simultaneously, the expression of PD-L1 protein is increased by JAK1-STAT3 signaling. The stem cells primed according to the present invention have improved stemness, and thus can be effectively used in the treatment of inflammatory diseases, immune diseases and the like.

IPC Classes  ?

• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

The present invention relates to: a pharmaceutical composition for preventing or treating retinitis pigmentosa comprising an agent for inducing a deletion of an IMPDH1 C.947G > C (p.ARG316PRO) mutation, and a method for preventing or treating retinitis pigmentosa, comprising a step of inducing the deletion of the mutation; a composition for diagnosing or predicting retinitis pigmentosa, comprising an agent for detecting an IMPDH1 C.947G > C (p.ARG316PRO) mutation; and a method for providing information for diagnosing or predicting retinitis pigmentosa, comprising a step of detecting the mutation.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 9/22 - Ribonucleases
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 27/02 - Ophthalmic agents

Abstract

An embodiment of the present invention provides an automated angiography system comprising: a catheter unit including a catheter and a connector coupled to the catheter and through which a guidewire passes; a contrast medium injection unit for injecting a contrast medium into the catheter unit; a driving unit for controlling movements of the catheter and the guidewire; an image information acquisition unit for acquiring image information about a region of interest into which the contrast medium is injected; and a control unit for controlling the driving unit to control the movements of the catheter or the guidewire by using the image information or controlling the contrast medium injection unit to adjust an injection speed and the amount of the contrast medium.

IPC Classes  ?

• A61B 6/50 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body partsApparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific clinical applications
• A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
• A61M 25/09 - Guide wires
• A61M 25/01 - Introducing, guiding, advancing, emplacing or holding catheters
• A61M 25/00 - CathetersHollow probes
• A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
• A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
• A61M 5/142 - Pressure infusion, e.g. using pumps

Abstract

According to an aspect, a pharmaceutical composition for the prevention or treatment of an intraretinal angiogenic disease, which contains vascular endothelial cells exhibiting reduced expression or activity of beta-2 microglobulin (B2M) and increased expression or activity of tyrosine kinase receptor 2 (Tie2) compared to parent cells, as an active ingredient, induces stabilization of vascular endothelial cells and reduces vascular permeability even in a state of inflammation or over-expression of vascular endothelial growth factors (VEGF), so as to slow down or inhibit intraretinal angiogenesis, thereby preventing or treating an intraretinal angiogenic disease. In addition, since the cells of the present invention survives for a long period due to low immunogenicity, the effect of inhibiting angiogenesis lasts for a long period after a single intraocular injection, and thus the present invention allows the treatment to proceed less invasively compared to conventional antibody therapies, enhances vascular stability, and enables early diagnosis and treatment of an intraretinal angiogenic disease.

IPC Classes  ?

• A61K 35/44 - VesselsVascular smooth muscle cellsEndothelial cellsEndothelial progenitor cells
• A61P 27/02 - Ophthalmic agents

Abstract

The present invention relates to a composition for diagnosing or predicting the prognosis of solid cancer (for example, lung cancer). In the present invention, association between the onset of solid cancer and an increase in the expression level of USE1 is identified, and an aptamer sequence capable of detecting USE1 with high specificity is provided. If the aptamer of the present invention is used, solid cancer can be rapidly and simply diagnosed in a non-invasive manner by detecting USE1 with high specificity.

IPC Classes  ?

• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

A biomarker composition for predicting susceptibility to a therapeutic agent for neurofibromatosis by using Ras activity; and a pharmaceutical composition for preventing or treating neurofibromatosis, including a Ras activity inhibitor. The biomarker composition can accurately diagnose susceptibility to a therapeutic agent for neurofibromatosis by measuring the expression levels of a GTP-bound and activated Ras (Ras-GTP) protein and an activated p-ERK protein or a gene encoding the same in a biological sample of an individual. The pharmaceutical composition inhibits the activity of Ras proteins, and thus can be effectively used for the prevention or treatment of neurofibromatosis in which the activity of the Ras proteins is increased.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• A61K 31/4245 - Oxadiazoles
• A61P 35/00 - Antineoplastic agents
• C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present specification provides a method for providing information on ulcerative colitis by means of a processor, the method comprising: a step for receiving a Korean Ulcerative Colitis-Specific Questionnaire (K-UCSQ) score for an individual; and a step for determining an inflammatory bowel disease prognosis for the individual on the basis of the received K-UCSQ score.

IPC Classes  ?

• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records

Abstract

The present invention relates to a pancreatic tumor diagnostic device, and to a pancreatic tumor diagnostic device, which can be easily fixed to the duodenal mucosa and enables rapid and accurate early diagnosis of pancreatic cancer. One aspect of the present invention can include: an insertion tube extending to be inserted into the body of a patient, and including a distal end portion and a proximal end portion; an endoscope cap, which is disposed to encompass the outer circumferential surface of the insertion tube, extends to have a length, and is disposed at a position spaced a predetermined distance apart from the distal end portion of the insertion tube; and a plurality of LED sensors disposed on the surface of the endoscope cap.

IPC Classes  ?

• A61B 5/1459 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters invasive, e.g. introduced into the body by a catheter
• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
• A61B 5/02 - Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor

Abstract

The present invention relates to an apparatus and method for providing virtual reality-based eye movement exercise and visual perception training, wherein a dichoptic presentation is provided in consideration of the deviation of a user's eyeball so as to prevent additional damage to stereoscopic vision due to suppression, and is provided by adjusting the degree of difficulty by changing the locations of visual stimuli on the basis of the level of deviation and training capability of the user, thus making it possible for the user to not only receive training suitable for the user's condition, but also simultaneously undergo visual perception training including eye exercise (movement) training and stereoscopic perception recognition.

IPC Classes  ?

• A61H 5/00 - Exercisers for the eyes
• A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
• G06T 7/00 - Image analysis
• G06T 7/20 - Analysis of motion
• G06T 7/70 - Determining position or orientation of objects or cameras
• G06T 19/00 - Manipulating 3D models or images for computer graphics

Abstract

This high-frequency cauterization device includes: a probe configured to be movable to a lesion site of a tissue; a first electrode disposed on the probe; a second electrode disposed on the probe so as to be spaced apart from the first electrode; a current generator for generating a current to be applied to the first electrode and the second electrode; and a controller which applies the current generated by the current generator to the first electrode and the second electrode, applies currents of different polarities to the first electrode and the second electrode, and controls the application of the current so that the polarities of the current applied to the first electrode and the current applied to the second electrode are switched on the basis of one or more switching modes.

IPC Classes  ?

• A61B 18/12 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
• A61B 18/14 - Probes or electrodes therefor
• A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body